…

For most auto-immune diseases, there is no therapy available which specifically targets the underlying root cause.

Patients are depending on non-curative treatments based on unspecific immune-suppression, and symptom management. Medraxa will initially focus on Multiple Sclerosis and Diabetes Type-1.

Multiple Sclerosis 2022: 25.9 bUSD2030: 34.36 bUSD (CAGR 3.6%) Diabetes Type 1 2022: 7.59 bUSD2030: 13.64 bUSD (CAGR 7.6%) [1,2]

Both MS and DT-1 current markets are characterized by underperformance due to lack of innovative treatment offers. We expect that Medraxa‘s novel therapeutic concept will hence allow for swift and strong market penetration.